Kymera Therapeutics Inc (KYMR) financials
Kymera Therapeutics revenue and earnings by year
Kymera Therapeutics's revenue was $39.2 million in the fiscal year to December 31, 2025, down 16.7% from the year before. Net income was -$311 million, -794.0% of revenue. Since the fiscal year to December 31, 2019, revenue has grown 54.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 39 | 47 | 79 | 47 | 73 | 34 | 3 |
| Revenue growth | -16.7% | -40.1% | 67.8% | -35.7% | 114.0% | 1060.0% | — |
| Operating income | -349 | -262 | -166 | -161 | -101 | -46 | -42 |
| Operating margin | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% | -136.1% | -1438.5% |
| Net income | -311 | -224 | -147 | -155 | -100 | -46 | -41 |
| Net margin | -794.0% | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% | -1405.8% |
| Diluted EPS | -$3.69 | -$2.98 | -$2.52 | -$2.87 | -$2.07 | — | — |
| Free cash flow | -234 | -207 | -137 | -156 | -131 | 79 | 17 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open KYMR in Markets.
See also: KYMR returns
No forecast, no recommendation. This page describes Kymera Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.